Novozymes A/S (OTCMKTS:NVZMY) Stock Rating Upgraded by Barclays

Novozymes A/S (OTCMKTS:NVZMY) was upgraded by research analysts at Barclays to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other brokerages have also recently commented on NVZMY. Citigroup cut Novozymes A/S from a “neutral” rating to a “sell” rating in a research report on Thursday, October 17th. Berenberg Bank upgraded Novozymes A/S to a “strong-buy” rating in a research report on Tuesday, September 24th.

Novozymes A/S Stock Performance

Novozymes A/S stock opened at $56.53 on Monday. Novozymes A/S has a 52 week low of $49.99 and a 52 week high of $72.50. The firm has a market capitalization of $26.47 billion, a price-to-earnings ratio of 35.78, a P/E/G ratio of 3.87 and a beta of 0.90. The company has a 50 day moving average price of $65.88 and a 200 day moving average price of $63.85.

Novozymes A/S Company Profile

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.